Pathogenesis of Primary Sclerosing Cholangitis and Advances in Diagnosis and Management
Open accessThe DOI matches its Crossref record; 174 of the 174 references it cites were found in a registry or an index.
Abstract
Primary sclerosing cholangitis (PSC), first described in the mid-1850’s, is a complex liver that is heterogeneous in its presentation. PSC is characterized by chronic cholestasis, associated with chronic inflammation of the biliary epithelium, resulting in multi-focal bile duct strictures that can affect the entire biliary tree. Chronic inflammation leads to fibrosis involving the hepatic parenchyma and biliary tree, which can lead to cirrhosis and malignancy. The etiology of PSC is not fully understood which in part explains a lack of effective medical therapy for this condition. However, we have begun to better understand the molecular pathogenesis of PSC. The recognition of specific clinical subtypes and their pattern of progression could improve phenotypic and genotypic classification of the disease. We review our current understanding of this enigmatic disorder and discuss important topics for future studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Korn, T., Bettelli, E., Oukka, M., & Kuchroo, V. K. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132710 · Cited by 4,873 · cited 1×
“Th17 cells have also been implicated in autoimmune diseases.(93) Compared with patients with autoimmune hepatitis or fatty liver disease, livers of patients with PSC contain higher number of Th17 cells, possibly a response to microbes.”
BackgroundEASL Clinical Practice Guidelines: management of cholestatic liver diseases
European Association for the Study of the Liver (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.04.009 · Cited by 1,729
Diagnosis and Management of Primary Sclerosing Cholangitis
Chapman, R., Fevery, J., Kalloo, A., Nagorney, D. M., Boberg, K. M., Shneider, B., & Gores, G. J. (2010) · Hepatology · doi:10.1002/hep.23294 · Cited by 1,224
Self-citationCairns, S. R., Scholefield, J. H., Steele, R. J., Dunlop, M. G., Thomas, H. J. W., Evans, G. D., Eaden, J. A., Rutter, M. D., Atkin, W. P., Saunders, B. P., et al. (2010) · Gut · doi:10.1136/gut.2009.179804 · Cited by 1,141
Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease
Sandborn, W. J., Gasink, C., Gao, L.-L., Blank, M. A., Johanns, J., Guzzo, C., Sands, B. E., Hanauer, S. B., Targan, S., Rutgeerts, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203572 · Cited by 1,134
Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy
Ghazale, A., Chari, S. T., Zhang, L., Smyrk, T. C., Takahashi, N., Levy, M. J., Topazian, M. D., Clain, J. E., Pearson, R. K., Petersen, B. T., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2007.12.009 · Cited by 890 · cited 2×
“Therefore, it is important to carefully exclude the presence of malignancy.(30) Future studies should help clarify the prevalence and outcomes of patients with PSC who have increased levels of IgG4 who do not meet the criteria for IAC.”
BackgroundSelf-citationNatural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis.
Broomé, U., Olsson, R., Lööf, L., Bodemar, G., Hultcrantz, R., Danielsson, A., Prytz, H., Sandberg-Gertzén, H., Wallerstedt, S., & Lindberg, G. (1996) · Gut · doi:10.1136/gut.38.4.610 · Cited by 819
Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis
Sandborn, W. J., Ghosh, S., Panes, J., Vranic, I., Su, C., Rousell, S., & Niezychowski, W. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112168 · Cited by 800
PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis
Loftus, E. V., Harewood, G. C., Loftus, C. G., Tremaine, W. J., Harmsen, W. S., Zinsmeister, A. R., Jewell, D. A., & Sandborn, W. J. (2005) · Gut · doi:10.1136/gut.2004.046615 · Cited by 777
Chapman, R. W., Arborgh, B. A., Rhodes, J. M., Summerfield, J. A., Dick, R., Scheuer, P. J., & Sherlock, S. (1980) · Gut · doi:10.1136/gut.21.10.870 · Cited by 732
Cited by
Burden of liver diseases in the world
Asrani, S. K., Devarbhavi, H., Eaton, J., & Kamath, P. S. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.09.014 · Cited by 3,783
Self-citationGlobal burden of liver disease: 2023 update
Devarbhavi, H., Asrani, S. K., Arab, J. P., Nartey, Y. A., Pose, E., & Kamath, P. S. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.03.017 · Cited by 2,267
Molecular and cellular mechanisms of liver fibrosis and its regression
Kisseleva, T., & Brenner, D. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00372-7 · Cited by 2,024
Primary Sclerosing Cholangitis
Lazaridis, K. N., & LaRusso, N. F. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1506330 · Cited by 505
Self-citationEpidemiology of gallbladder cancer
Rawla, P., Sunkara, T., Thandra, K. C., & Barsouk, A. (2019) · Clinical and Experimental Hepatology · doi:10.5114/ceh.2019.85166 · Cited by 354
Bile Acid Metabolism and Signaling in Cholestasis, Inflammation, and Cancer
Li, T., & Apte, U. (2015) · Advances in Pharmacology · doi:10.1016/bs.apha.2015.04.003 · Cited by 333
Immunity, tolerance and autoimmunity in the liver: A comprehensive review
Doherty, D. G. (2016) · Journal of Autoimmunity · doi:10.1016/j.jaut.2015.08.020 · Cited by 314
Liver diseases: epidemiology, causes, trends and predictions
Gan, C., Yuan, Y., Shen, H., Gao, J., Kong, X., Che, Z., Guo, Y., Wang, H., Dong, E., & Xiao, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02072-z · Cited by 310
Aabakken, L., Karlsen, T., Albert, J., Arvanitakis, M., Chazouilleres, O., Dumonceau, J.-M., Färkkilä, M., Fickert, P., Hirschfield, G., Laghi, A., et al. (2017) · Endoscopy · doi:10.1055/s-0043-107029 · Cited by 255
Distinctive inflammatory bowel disease phenotype in primary sclerosing cholangitis
Vries, A. B. D. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i6.1956 · Cited by 253
Deneau, M. R., El‐Matary, W., Valentino, P. L., Abdou, R., Alqoaer, K., Amin, M., Amir, A. Z., Auth, M., Bazerbachi, F., Broderick, A., et al. (2017) · Hepatology · doi:10.1002/hep.29204 · Cited by 230
Macrophages contribute to the pathogenesis of sclerosing cholangitis in mice
Guicciardi, M. E., Trussoni, C. E., Krishnan, A., Bronk, S. F., Lorenzo Pisarello, M. J., O'Hara, S. P., Splinter, P. L., Gao, Y., Vig, P., Revzin, A., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.05.018 · Cited by 183
“Patients with PSC are at high risk for the development of cirrhosis and its sequela of portal hypertension, end-stage liver disease, and cholangiocarcinoma.(1) Animal models contribute to our knowledge of disease pathogenesis and malignant transformation of the biliary epithelia, and provide insight regarding new ther…”
Self-citationAabakken, L., Karlsen, T. H., Albert, J., Arvanitakis, M., Chazouilleres, O., Dumonceau, J.-M., Färkkilä, M., Fickert, P., Hirschfield, G. M., Laghi, A., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.02.013 · Cited by 107
“If high quality MRC images are not available, or in equivocal cases, it is reasonable to consider patient referral to centers with known technical expertise with MRC as a first step [19], followed by liver biopsy.”
Kunzmann, L. K., Schoknecht, T., Poch, T., Henze, L., Stein, S., Kriz, M., Grewe, I., Preti, M., Hartl, J., Pannicke, N., et al. (2020) · Hepatology · doi:10.1002/hep.31140 · Cited by 93
“PB C (n = 9 9) 14 /8 5 61 (2 589 ) 7 (0 -3 0) 32 (1 088 ) 13 1 (4 740 6) 0.”
BackgroundInfluentialChristensen, B., Micic, D., Gibson, P. R., Yarur, A., Bellaguarda, E., Corsello, P., Gaetano, J. N., Kinnucan, J., Rao, V. L., Reddy, S., et al. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14525 · Cited by 91
“Biopsies in CD and UC were scored on a 4-point scale as quiescent/normal (0), mild (1), moderate (2) or severe (3).”
MethodLow risk of hepatocellular carcinoma in patients with primary sclerosing cholangitis with cirrhosis
Zenouzi, R., Weismüller, T. J., Hübener, P., Schulze, K., Bubenheim, M., Pannicke, N., Weiler–Normann, C., Lenzen, H., Manns, M. P., Lohse, A. W., et al. (2014) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.02.008 · Cited by 86
Rupp, C., Hippchen, T., Bruckner, T., Klöters-Plachky, P., Schaible, A., Koschny, R., Stiehl, A., Gotthardt, D. N., & Sauer, P. (2019) · Gut · doi:10.1136/gutjnl-2018-316801 · Cited by 73
Eaton, J. E., Welle, C. L., Bakhshi, Z., Sheedy, S. P., Idilman, I. S., Gores, G. J., Rosen, C. B., Heimbach, J. K., Taner, T., Harnois, D. M., et al. (2021) · Hepatology · doi:10.1002/hep.31575 · Cited by 56
“Images were classified as either (1) definite CCA, (2) possible CCA (should proceed with additional testing), or (3) negative for CCA (Fig.”
BackgroundMethodResultSelf-citationEaton, J. E., Sen, A., Hoodeshenas, S., Schleck, C. D., Harmsen, W. S., Gores, G. J., LaRusso, N. F., Gossard, A. A., Lazaridis, K. N., & Venkatesh, S. K. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2019.10.041 · Cited by 56
Self-citationYounossi, Z. M., Afendy, A., Stepanova, M., Racila, A., Nader, F., Gomel, R., Safer, R., Lenderking, W. R., Skalicky, A., Kleinman, L., et al. (2018) · Hepatology · doi:10.1002/hep.29664 · Cited by 48
Fine‐Tuning of Sirtuin 1 Expression Is Essential to Protect the Liver From Cholestatic Liver Disease
Blokker, B. A., Maijo, M., Echeandia, M., Galduroz, M., Patterson, A. M., Ten, A., Philo, M., Schungel, R., Gutierrez‐de Juan, V., Halilbasic, E., et al. (2019) · Hepatology · doi:10.1002/hep.30275 · Cited by 46
“700 disease.(1-3) Current therapeutic approaches for treating cholestasis mainly rely on the use of ursodeoxycholic acid (UDCA); however, this treatment has no proven efficacy for PSC and a proportion of patients with PBC.”
BackgroundTh17 cell frequency is associated with low bone mass in primary sclerosing cholangitis
Schmidt, T., Schwinge, D., Rolvien, T., Jeschke, A., Schmidt, C., Neven, M., Butscheidt, S., Kriz, M., Kunzmann, L., Mussawy, H., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.12.035 · Cited by 42
Rupp, C., Bode, K. A., Chahoud, F., Wannhoff, A., Friedrich, K., Weiss, K.-H., Sauer, P., Stremmel, W., & Gotthardt, D. N. (2014) · BMC Infectious Diseases · doi:10.1186/s12879-014-0562-8 · Cited by 38
“Background Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease characterized by inflammation and stricture formation of the intra- and extrahepatic biliary system, which progresses to liver cirrhosis in the majority of cases [1-3].”
BackgroundThe Human Gut Microbiome in Liver Diseases
Davis, B., & Bajaj, J. (2017) · Seminars in Liver Disease · doi:10.1055/s-0037-1602763 · Cited by 34
Roles of Trained Immunity in the Pathogenesis of Cholangiopathies: A Therapeutic Target
Yan, C., Koda, S., Wu, J., Zhang, B., Yu, Q., Netea, M. G., Tang, R., & Zheng, K. (2020) · Hepatology · doi:10.1002/hep.31395 · Cited by 21
“Re fe re nc es (1 7, 74 ,7 5) (1 7, 76 -7 8) (7 9, 80 ) (8 184 ) (6 0, 61 ,8 587 )”
Metadata
- Authors
- Eaton, J. E., Talwalkar, J. A., Lazaridis, K. N., Gores, G. J., & Lindor, K. D.
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2013-09
- Volume
- 145
- Issue
- 3
- Pages
- 521-536
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W2170004041
- Cited by
- 436
- References
- 174
- FWCI
- 19.64
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.